Streetbeat News

DNTH

Dianthus Therapeutics, Inc.

Industry

Biotechnology

Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.

Open

21.77

Mkt cap

685M

Volume

168K

High

22.10

P/E Ratio

-8.36

52-wk high

33.77

Low

21.23

Div yield

N/A

52-wk low

18.13

Dianthus Therapeutics reported its Q4 and FY 2024 financial results, highlighting ongoing clinical trials for DNTH103 in various autoimmune diseases. The company has $357 million in cash, providing a financial runway into the second half of 2027.

Portfolio Pulse from

March 11, 2025 | 8:15 pm

Dianthus Therapeutics has appointed John C. King as Chief Commercial Officer and Sujay Kango to its Board of Directors. King has a strong background in launching biologics and C5 complement inhibitors, which could enhance Dianthus's strategic commercial leadership.

Portfolio Pulse from

March 05, 2025 | 12:15 pm

Dianthus Therapeutics, Inc. (Nasdaq: DNTH) will participate in two upcoming investor conferences. The company focuses on developing antibody complement therapeutics for severe autoimmune diseases.

Portfolio Pulse from

February 26, 2025 | 12:15 pm

Dianthus Therapeutics, Inc. (Nasdaq: DNTH) will present at two healthcare investor conferences in February, showcasing their advancements in antibody complement therapeutics for autoimmune diseases.

Portfolio Pulse from

January 30, 2025 | 12:15 pm

Dianthus Therapeutics, Inc. (DNTH) reported a Q3 loss of $0.74 per share, which was larger than the Zacks Consensus Estimate of a $0.59 loss. However, the company topped revenue estimates.

Portfolio Pulse from

November 08, 2024 | 12:00 am

Dianthus Therapeutics has announced its Q3 financial results and highlighted recent business achievements. The company plans to initiate a pivotal Phase 3 trial of DNTH103 for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) by the end of 2024.

Portfolio Pulse from

November 07, 2024 | 9:15 pm

Oppenheimer has initiated coverage on Dianthus Therapeutics with an Outperform rating and set a price target of $48.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 12:06 pm

Dianthus Therapeutics (NASDAQ:DNTH) has been evaluated by 4 analysts over the past three months, with ratings ranging from bullish to bearish. The average 12-month price target has increased by 10.6% to $43.5. Analysts have maintained or adjusted their ratings and price targets, reflecting their views on the company's market position. Dianthus Therapeutics, a clinical-stage biotech company, has shown significant revenue growth but faces challenges in profitability and asset utilization.

Portfolio Pulse from Benzinga Insights

September 26, 2024 | 12:00 pm

HC Wainwright & Co. has reiterated its Buy rating on Dianthus Therapeutics (NASDAQ:DNTH) and maintained a $40 price target, indicating confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 10:38 am

Ulta Beauty reported disappointing Q2 results, missing earnings and sales estimates, and cut its FY24 guidance, leading to a 6.4% drop in pre-market trading. Elastic also saw a significant decline of 27.1% after issuing weak revenue guidance.

Portfolio Pulse from Avi Kapoor

August 30, 2024 | 12:29 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.